Generalist Data Handling is a Regulatory Liability
In Biotech and Pharma, data is not just numbers in a spreadsheet—it is scientific evidence. When generalist IT vendors manage clinical trial analytics, they lack the domain-specific rigor and regulatory depth required for high-stakes submissions. This creates a dangerous Translation Gap that leads to statistical anomalies, fragile data pipelines, and catastrophic delays in FDA/EMA submissions.
Designial anchors your data in clinical science. We replace generalist developers with dedicated biostatistical engineering pods under the direct supervision of veteran scientists. Every line of analysis, database structure, and automated report is built to stand up to the most demanding regulatory audits.
Agentic AI for BioTech & Pharma
Foundational engineering pods built to architect, scale, and secure your proprietary R&D data pipelines for clinical trial excellence.
Autonomous CSR Drafting
Processing raw trial data, automating CDISC formatting, and drafting complete Clinical Study Reports (CSRs) to dramatically shorten submission timelines.
Governed by senior biostatisticians and medical writing veterans.
Clinical Trial Screening AI
Building predictive cohort selection models and patient screening agents to identify high-efficacy trial populations and eliminate enrollment bottlenecks.
Mentored by clinical trial architects and medical research scientists.
Data Integrity Vaults
Architecting 21 CFR Part 11 and GxP compliant data environments featuring sovereign residency shielding, model-weight isolation, and robust audit logging.
Forensic data audit by 40-year biostatistics deans and legal counsel.
Build Your Scientific Engine
Deploy your specialized Agentic AI workforce through our biostatistics-governed infrastructure to de-risk your clinical submissions.
The Data Integrity Shield: Practitioner-Led Technical Governance
We eliminate the Translation Gap through a three-phase governance model that ensures your clinical data is secure, compliant, and submission-ready from day one.
Phase I: Protocol Alignment
Aligning every data pipeline, repository structure, and analysis algorithm with US FDA and EMA standards before processing begins.
Phase II: Real-Time Peer Review
Testing all biostatistical outputs and database operations against high-stakes validation scripts under the guidance of our Advisory Council.
Phase III: Regulatory Signature
Final verification of database structures, statistical calculations, and data transfers by senior biostatistics practitioners.
Book a Governance Consultation
Accelerating Your Path to Market
For Biotech scale-ups and high-growth Pharma firms, clinical runway is everything. By establishing a Scientifically-Anchored 2nd HQ with Designial, you reduce R&D burn by 40-60% while accelerating execution velocity.
We transform your biostatistical operations from a costly administrative burden into a high-valuation technical asset. We build your proprietary Data Integrity Vault, giving you complete IP sovereignty and a self-sustaining asset optimized for clinical success.
Scientific Data Governance FAQs
Compliance | How do we guarantee GxP and Part 11 compliance?
Generalist outsourcing vendors often compromise security by hosting clinical trial data in shared, multi-tenant cloud environments. Designial de-risks this by constructing a private, sovereign Data Integrity Vault tailored specifically to the strict compliance demands of 21 CFR Part 11 and GxP (Good Clinical Practices). This architecture implements secure multi-region database siloing, model-weight isolation to protect proprietary trial algorithms, and unalterable cryptographic audit trails for all data operations. Guided by our legal advisors, we guarantee that all data handling complies with US FDA, European GDPR, and India’s DPDP Act.
Integration | Can our data pods integrate with traditional pharmaceutical research systems?
Yes. We design our biostatistical engineering pods with highly configurable data connectors designed to interface with traditional pharmaceutical environments (such as SAS, R, or legacy EDC platforms) without data loss or pipeline fragmentation. Our teams construct secure data mapping layers that automate SDTM/ADaM formatting and streamline trial analytics, preserving your historical data investments while preparing your infrastructure for modern, AI-native scaling.
Ownership | How do we protect proprietary drug and target IP?
Under our Build-Operate-Transfer (BOT) framework, your clinical data and drug-target models never touch shared servers. We construct a 100% private, sovereign engineering hub dedicated solely to your pharma enterprise. All custom codebases, data pipelines, and trained model weights remain your exclusive intellectual property. At the end of the incubation lifecycle, we execute a seamless legal handover of the entire Indian entity and its specialized clinical talent directly to your parent company, transferring a high-value, fully compliant R&D asset to your corporate balance sheet.
Operational Velocity | How do we accelerate trial data and CSRs?
Clinical Study Report (CSR) drafting is traditionally a massive operational bottleneck, requiring manual data collation, CDISC conversion, and intensive medical writing. Designial’s biostatistics pods utilize Agentic AI engineered to directly process SDTM/ADaM datasets. Guided by the clinical reasoning of senior biostatisticians and 40-year FDA regulatory veterans, our autonomous agents systematically format data to CDISC standards and draft complete regulatory-grade CSRs. This practitioner-led approach reduces the administrative burden on clinical operations teams, de-risks submission data, and shortens clinical trial runways by up to 50%.
Stop Building in a Vacuum. Start Building with Scientists.
Deploy your autonomous biostatistics workforce to bridge the Translation Gap and accelerate your clinical runway